10-Q: Plus Therapeutics Boosts Cash, Equity Amid Nasdaq Scrutiny

Plus Therapeutics reported a significant increase in cash and a shift to positive stockholders' equity in Q2 2025, driven by recent capital raises, despite ongoing operational losses and Nasdaq listing challenges.

Summary

• Net income for the three months ended June 30, 2025, was $5.151 million, a significant improvement from a net loss of $2.940 million in the same period of 2024.
• The company's cash and cash equivalents increased to $2.233 million as of June 30, 2025, up from $0.076 million at December 31, 2024.
• Stockholders' equity turned positive to $3.034 million as of June 30, 2025, compared to a deficit of $8.949 million at December 31, 2024.
• Working capital improved to $1.898 million from a deficit of $10.292 million.
• Net loss for the six months ended June 30, 2025, increased to $12.250 million from $6.201 million in the prior year period.
• Net cash used in operating activities for the six months ended June 30, 2025, was $11.970 million, an increase from $5.663 million in the same period of 2024.
• The company raised approximately $15.0 million in gross proceeds from a March 2025 Private Placement and $2.8 million from the Lincoln Park Purchase Agreement by June 30, 2025.
• The FDA cleared the Investigational New Drug (IND) application for REYOBIQ for pediatric brain cancer (ReSPECT-PBC trial) on June 25, 2025.
• The ReSPECT-LM Phase 1 trial was completed on February 26, 2025, with the Cohort 4 dose (44.1 mCi) determined as the recommended Phase 2 dose, and one patient achieving a complete response.
• The company initiated the ReSPECT-LM dose optimization trial on June 30, 2025, and treated initial patients on July 8, 2025.
• Interim data from the ReSPECT-GBM Phase 2 trial (as of September 30, 2024) showed a favorable safety profile, an average absorbed radiation dose to the tumor of 300 Gy, and a statistically significant reduction in tumor volume rate change.
• The CNSide Platform, acquired in April 2024, is planned for re-introduction to the U.S. market in the second half of 2025, starting in Texas.
• The company received a $3.0 million award from the Department of Defense for pediatric brain cancer research and development.
• The company received a $17.6 million CPRIT Grant for the development of REYOBIQ for leptomeningeal metastases, with approximately $12.4 million received as of June 30, 2025.
• The company regained Nasdaq Minimum Stockholders Equity Requirement compliance on March 7, 2025, but later received a new delisting notice on June 3, 2025, for falling out of compliance again, with a new deadline of August 14, 2025.
• The company received a Nasdaq notice on May 16, 2025, for non-compliance with the Minimum Bid Requirement ($1.00/share), with a compliance period until November 12, 2025.
• Stockholders granted discretionary authority to the board for a reverse stock split (1-for-25 to 1-for-250) on May 2, 2025, to address the bid price deficiency if necessary.

Sentiment

Score: 6

Explanation: While the company achieved a positive net income for the quarter and significantly improved its cash and equity position through recent financings, it continues to face substantial operational losses and ongoing Nasdaq listing challenges. Positive clinical progress and strategic acquisitions are promising, but the 'going concern' warning and reliance on future capital raises indicate continued financial fragility.

Positives

• Achieved net income of $5.151 million for the three months ended June 30, 2025, reversing a prior year loss.
• Significantly increased cash and cash equivalents to $2.233 million, providing improved liquidity.
• Successfully shifted from a stockholders' deficit to positive equity of $3.034 million.
• Improved working capital position to a positive $1.898 million from a significant deficit.
• Secured substantial capital through the March 2025 Private Placement ($15.0 million gross) and the Lincoln Park Purchase Agreement (up to $50.0 million, with $2.8 million already raised).
• FDA cleared the IND for the ReSPECT-PBC (pediatric brain cancer) clinical trial, advancing the pipeline.
• Completed Phase 1 of the ReSPECT-LM trial, identifying a recommended Phase 2 dose and observing a complete response in one patient.
• Initiated the ReSPECT-LM dose optimization trial, demonstrating continued clinical progress.
• Interim data from ReSPECT-GBM Phase 2 trial showed favorable safety and promising tumor response, including high absorbed radiation doses.
• Acquired and is planning the re-introduction of the CNSide Platform, a diagnostic tool with demonstrated high sensitivity and clinical utility.
• Received Orphan Drug Designation and Fast Track designations for REYOBIQ across multiple indications (GBM, LM, breast cancer with LM, lung cancer with LM).
• Secured significant grant funding, including a $3.0 million DoD Award and a $17.6 million CPRIT Grant.

Negatives

• Reported an increased net loss of $12.250 million for the six months ended June 30, 2025, compared to $6.201 million in the prior year.
• Experienced a higher net cash burn from operating activities, increasing to $11.970 million for the six months ended June 30, 2025.
• The company continues to operate with substantial doubt about its ability to continue as a going concern.
• Faces ongoing Nasdaq listing compliance issues, including non-compliance with the Minimum Bid Requirement and a renewed non-compliance notice for the Minimum Stockholders Equity Requirement.
• Significant share dilution occurred due to recent capital raises, with weighted average shares outstanding increasing substantially.
• Interest income decreased due to lower average cash and investment balances and a higher interest rate environment in the prior year.

Risks

• Substantial doubt about the ability to continue as a going concern due to accumulated deficit and ongoing operating losses.
• Inability to raise additional capital in the future would materially and adversely impact operations and ability to satisfy obligations.
• Risk of delisting from Nasdaq for failure to comply with the Minimum Stockholders Equity Requirement (deadline August 14, 2025) or the Minimum Bid Requirement (deadline September 8, 2025).
• Early stage of product candidates and therapies, with inherent uncertainties relating to clinical trials and regulatory approvals.
• Reliance on grant funding, with potential repayment obligations if certain conditions are not met or the company relocates.
• Volatility in global markets could cause interest rates to fluctuate, increasing costs, or affect credit facility availability.
• Need to significantly reduce or curtail research and development and other operations if sufficient capital is not raised.
• Potential for further share dilution if a reverse stock split is implemented or additional capital is raised through equity offerings.

Future Outlook

The company anticipates increasing research and development expenses for the remainder of 2025 as it commences the ReSPECT-LM dose optimization trial and prepares for the commercial launch of CNSide Diagnostics. General and administrative expenditures are also expected to increase due to the CNSide launch requiring additional administrative and sales headcount. The company continues to seek additional capital to fund future clinical development programs, commercialization of CNSide, and other operations, acknowledging that its inability to raise sufficient funds would materially and adversely impact its operations and ability to achieve corporate growth goals.

Management Comments

• "We are planning for the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test (the 'CNSide Test'), which is a laboratory developed test (LDT), to be re-introduced to the U.S. market starting in the second half of 2025 after we complete a number of steps related to certifications, state licensure, payor coverages, reimbursement codes and financing."
• "We anticipate beginning enrollment for our Phase 1 ReSPECT-PBC clinical trial in 2025."
• "We expect aggregate research and development expenses to increase during the remainder of 2025 as compared to the corresponding comparable period in 2024 as we commence the ReSPECT-LM dose optimization trial for REYOBIQ and prepare for the launch of CNSide Diagnostic."
• "We expect general and administrative expenditures to increase during the remainder of 2025 as compared to the corresponding comparable period in 2024 as we work towards the commercial launch of CNSide, which will require an increase in administrative and sales headcount."

Industry Context

The company operates in the high-need areas of radiotherapeutics and CNS diagnostics, focusing on aggressive cancers like glioblastoma and leptomeningeal metastases, which currently have limited effective treatments. Its strategy aligns with the broader industry trend towards precision medicine and targeted therapies, aiming to deliver higher, more localized radiation doses with reduced systemic toxicity. The re-introduction of the CNSide diagnostic platform addresses a critical need for improved tumor cell detection and biomarker identification in LM, a growing complication in late-stage cancer, positioning the company to capitalize on advancements in personalized oncology.

Comparison to Industry Standards

• REYOBIQ is designed to deliver radiation doses up to 20 times greater than external beam radiation therapy (EBRT), while sparing normal tissue, addressing a key limitation of traditional treatments for GBM.
• Unlike EBRT, REYOBIQ is administered in a single, short, in-patient hospital visit, offering a more convenient treatment schedule compared to EBRT's typical four to six weeks of daily outpatient visits.
• The CNSide Test demonstrated significantly enhanced diagnostic sensitivity (80%) compared to the gold standard cerebrospinal fluid cytology (29%) in patients with LM, indicating a substantial improvement in detection capabilities.
• The CNSide Test influenced clinical management decisions in over 90% of LM cases evaluated in the FORESEE trial, surpassing the predetermined 20% primary endpoint target, highlighting its practical utility in guiding treatment strategies.

Corporate Governance

Related Party Transactions

• The May 2024 Private Placement included participation from certain of the company's directors and executive officers (Company Insiders).

Stakeholder Impact

• Shareholders face significant dilution from recent capital raises and the potential for further dilution or a reverse stock split, alongside ongoing Nasdaq delisting risks.
• Employees may see increased opportunities and headcount, particularly in administrative and sales roles, as the company prepares for the CNSide commercial launch.
• Future customers could benefit from the development of new targeted radiotherapeutics for CNS cancers and improved diagnostic tools like the CNSide Test.
• Creditors have seen repayment of certain debt facilities, but the company's 'going concern' status indicates continued reliance on external financing.
• Partners like CPRIT and the Department of Defense are key funding sources, supporting the company's R&D efforts.

Next Steps

• Target full enrollment for the ReSPECT-GBM Phase 2 trial by the end of 2025.
• Expect a data read-out for the ReSPECT-GBM trial by the end of 2025.
• Prepare a clinical study report and manuscript for the completed ReSPECT-LM Phase 1 trial.
• Anticipate beginning enrollment for the Phase 1 ReSPECT-PBC clinical trial in 2025.
• Re-introduce the CNSide Test to the U.S. market starting in the second half of 2025, initially in Texas.
• Expand CNS testing capabilities over the next year.
• Negotiate a commercial supply agreement with SpectronRx for drug product manufacturing.
• Demonstrate compliance with the Nasdaq Minimum Stockholders Equity Requirement by August 14, 2025.
• Demonstrate compliance with the Nasdaq Minimum Bid Requirement by September 8, 2025.
• Consider implementing a reverse stock split if necessary to regain Nasdaq bid price compliance.
• Continue efforts to raise additional capital to fund future clinical development and operations.
• Expect aggregate research and development expenses to increase during the remainder of 2025.
• Expect general and administrative expenditures to increase during the remainder of 2025 to support CNSide commercial launch.

Key Dates

Recommendation

The company presents a mixed financial picture with improved cash and equity positions driven by recent capital raises, but persistent operational losses and ongoing Nasdaq listing compliance challenges. While clinical progress with REYOBIQ and the CNSide Platform is promising and addresses high unmet medical needs, the 'going concern' warning and the need for continuous capital infusion introduce significant risk. A seasoned investor would likely 'hold' to monitor the company's ability to resolve Nasdaq compliance issues and achieve key clinical and commercial milestones, as these will be critical determinants of future valuation.

Keywords

Radiotherapeutics, CNS cancers, Glioblastoma, Leptomeningeal metastases, Pediatric brain cancer, REYOBIQ, CNSide Platform, Oncology, Clinical trials, FDA, Nasdaq compliance, Biotechnology, Drug development, Medical device, Cancer diagnostics